RFK Jr. and the 2026 Peptide Policy: What He Signed

The October 28 public-inspection notice ends with Robert F. Kennedy Jr.’s name and title as Secretary of Health and Human Services. Its action is a notice of availability. It introduces a draft enforcement-discretion policy concerning the use of certain peptide bulk drug substances in section 503A compounding.

That gives readers a concrete way to understand headlines about “RFK peptides.” The Secretary’s signature identifies the official announcing the policy. It does not turn the document into six new-drug approvals, establish a dosing label, or prove a clinical benefit for the conditions discussed online.

The linked HHS document lists six specific forms: BPC-157 acetate, TB-500 acetate, Epitalon acetate, Semax free base, KPV acetate, and MOTS-c acetate. The scope concerns section 503A, not an extension to 503B outsourcing facilities. The draft specifies single-API preparations, matching identities and routes, qualified original manufacturers, testing and traceability, labeling, reporting, and patient-specific prescriptions. It does not cover a BPC-157/TB-500 blend merely because both names appear on the list. Those conditions are central to what the Secretary announced.

In the notice, HHS describes an interest in expanding access while the bulks list is developed through rulemaking. That stated purpose is not a guarantee that access will immediately expand in a particular state, clinic, or pharmacy. Patient assessment, professional requirements, sourcing, and the preparation itself still matter.

The FDA Pharmacy Compounding Advisory Committee considered peptide bulk substances in July 2026. Advisory recommendations are not binding drug approvals. The committee’s role was to advise on compounding-list questions, not approve every medical claim associated with a peptide.

The OIRA review record shows a policy received October 14 and a review concluded October 27 as “Consistent with Change.” OIRA is within the White House’s Office of Management and Budget. That process supports saying the policy completed regulatory review. It does not support saying the White House independently certified the six substances as effective treatments. Keep agency advice, policy review, and final drug approval separate.

The signed notice directly states that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. It also says HHS may revisit the interim approach if a safety signal or quality issue arises. Those statements belong in the explanation of the announcement, not in a hidden footnote.

The same notice calls the policy draft and nonbinding. It schedules Federal Register publication for October 30 and allows written comments for two weeks after publication. These details make “RFK approved six safe peptides” an inaccurate shortcut. Political support for access and scientific evidence for a treatment answer different questions.

Use it as a reason to ask better questions, not as a reason to choose a substance. Start with the health concern: what diagnosis is being addressed, what options have stronger evidence, and what benefit would count as meaningful? Ask what is known about the proposed formulation and what remains uncertain.

If compounding is discussed, request the exact ingredient form, pharmacy identity, reason for compounding, and follow-up plan. A familiar political figure, a pharmacy license, or a clinician’s recommendation does not replace disclosure about an unapproved product. Our main policy guide explains the six-substance scope; the timeline separates completed events from scheduled next steps. Nothing in this article confirms Peppy availability or a particular patient’s eligibility.